TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro
US11072647B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 29, 2018 |
| Grant date | Jul 27, 2021 |
| Priority date | — |
| Expiry date | Dec 15, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An isoform of the TGF beta receptor II comprising a sequence of about of 80 amino acids and lacking a transmembrane domain. The isoform comprises the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2. A fusion peptide is provided comprising an isoform of the TGF beta II receptor fused to a ligand, wherein a vector comprising the fusion peptide is used to treat cancer and/or hepatic fibrosis. An antibody binding the soluble isoform of the TGF beta II receptor is provided. The antibody binds the amino acid sequence shown in SEQ ID No. 12 and is used in in vitro methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.